YD Bio management commentary cites larger drug, medical product orders driving H1 2026 revenue up to $0.8 million

• In management commentary for the six months ended June 30, 2026, net revenue rose to $846,501 from $204,007.
• Management attributed the gain to expanded business with existing clients, higher visibility, several sizable orders, led by a $327,060 drug order.
• Cost of revenue climbed to $578,271 from $135,212, with management citing lower margins on the large order.
• Operating expenses increased to $3.5 million from $2.02 million, driven by staffing expansion, marketing spend, professional fees, R&D tied to licensed patents.
• Net income was $6.7 million versus a $1.92 million loss, largely reflecting a $9.85 million gain from warrant liability fair-value changes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-095815), on September 01, 2026, and is solely responsible for the information contained therein.